Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Peginterferon alfa-2b is a synthetic (recombinant) form of interferon alpha conjugated with polyethylene glycol to extend its half-life. It acts as an immunomodulatory and antiviral agent by binding to human type 1 interferon receptors (IFNAR1 and IFNAR2), activating the JAK/STAT signaling pathway. This leads to increased expression of genes involved in the innate antiviral response and inhibition of viral replication. Peginterferon alfa-2b is primarily used for the treatment of chronic hepatitis C infection in combination with ribavirin or other agents in patients who have not previously received interferons. It is also approved for use as adjuvant therapy to reduce recurrence risk after surgical removal of malignant melanoma[1][3][4]. The drug has been largely replaced by direct acting antivirals for hepatitis C but remains relevant in certain clinical settings.
- Brand names
- PEG-IntronPeg Intron RPSylatron
- Other names
- peginterferon alpha-2bPEG-IntronSylatron
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b.